Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $97.50 short put and a strike $92.50 long put offers a potential 8.93% return on risk over the next 36 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $97.50 by expiration. The full premium credit of $0.41 would be kept by the premium seller. The risk of $4.59 would be incurred if the stock dropped below the $92.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Elanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes
Wed, 15 Aug 2018 01:25:00 +0000
Elanco will place the net proceeds of the Offering into escrow, to be released upon either the completion of its previously announced, anticipated initial public offering (IPO) or a special mandatory redemption, which would occur if the IPO does not take place, or Lilly otherwise determines that the IPO will not take place, by June 30, 2019. Elanco intends to pay the net proceeds of the Offering as part of the consideration to Lilly.
Analyzing Nektar Therapeutics’ Financial Performance
Tue, 14 Aug 2018 19:02:50 +0000
Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017.
Pfizer Is Expected to Report Modest Revenue Rise in Fiscal 2018
Tue, 14 Aug 2018 12:10:00 +0000
In its Q2 2018 earnings conference call, Pfizer (PFE) updated its fiscal 2018 revenue guidance from the previously projected range of $53.5 billion–$55.5 billion to $53.0 billion–$55.0 billion, mainly to account for the unfavorable foreign currency fluctuations from mid-April 2018 to mid-July 2018. Analysts have projected Pfizer’s fiscal 2018 revenues to come in around $54.2 billion, which would be a year-over-year (or YoY) rise of approximately 3.1%. Merck (MRK), Eli Lilly (LLY), and Novartis (NVS) are expected to report revenues close to $42.4 billion, $24.3 billion, and $52.4 billion, respectively, in fiscal 2018.
Novo Nordisk’s Fast-Acting Insulins: A Performance Overview
Tue, 14 Aug 2018 11:31:47 +0000
In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, reflecting a ~2% YoY (year-over-year) growth in local currencies.
Mylan Launches First Adcirca Generic, Stock Moves Up
Mon, 13 Aug 2018 20:45:22 +0000
Today, Mylan Pharmaceuticals (MYL) announced the launch of tadalafil tablets USP (20 mg) in the United States. The drug is the first generic version of Eli Lilly’s (LLY) Adcirca (tadalafil) approved by the FDA.
Also on Market Tamer…
Follow Us on Facebook